Faeq Mansour

Senior Director, Head Of IT at FibroGen

Faeq Mansour has a solid work experience in the field of Information Technology, specifically in the pharmaceutical and biotechnology industries. Faeq has held various leadership positions throughout their career, starting with their current role as the Senior Director of IT PMO and R&D Applications at FibroGen, Inc. since February 2023.

Prior to this, Faeq served as the Senior Director and Head of Corporate IT at Atomwise from January 2022 to December 2022. Faeq also worked at BridgeBio as the Senior Director of IT Strategy and Operations from April 2021 to December 2021.

Before joining BridgeBio, Faeq held multiple roles at Ultragenyx Pharmaceutical Inc., including Director of Information Technology Operations from February 2019 to April 2021 and Associate Director of IT from June 2016 to January 2019.

Earlier in their career, Faeq worked at BioMarin as a Senior Manager of Enterprise Application from April 2012 to June 2016, and at Genentech as a Senior System Specialist from September 1997 to March 2012.

Based on these positions, it's clear that Faeq Mansour has accumulated a wealth of experience in IT leadership roles within the pharmaceutical and biotech industries.

Faeq Mansour's education history includes studying Microbiology, General at San Jose State University. The dates of enrollment and completion are not specified. Furthermore, Faeq pursued a Master of Computer Applications (MCA) degree at the University of Phoenix. However, the dates of enrollment and completion for this degree are also unspecified.

Links

Previous companies


Org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


FibroGen

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.


Industries

Employees

501-1,000

Links


This is an unverified company page